Vertex Pharmaceuticals Selects TRIA to Design Laboratory and Office for New 268,000 SF VCGT Research Site

BOSTON– TRIA, a principal-led architecture firm with a focus on designing unique workspaces for science, technology, and corporate clients, announced today that it is designing a new cell and genetic therapies research site in the Boston area for Vertex Pharmaceuticals, Inc. (Nasdaq: VRTX), a global biotechnology company. The Vertex Cell and Genetic Therapies site will house the company’s research, development, and clinical manufacturing activities for cell and genetic therapies – two rapidly emerging therapeutic modalities with the potential to treat—and even cure—several of the diseases Vertex is focused on. TRIA was selected to provide architectural services for the design and build-out of laboratory, office, and amenity spaces for Vertex’s newly constructed 268,000 SF research site.

Ex-GSK Shingrix chief Guillaume Pfefer lands at Flagship as its second CEO-partner

It’s back to biotech for Dr. Guillaume Pfefer, and not a moment too soon. Having spent four years at GlaxoSmithKline ushering its shingles vaccine through approval and onto the market, he’s now taking on the dual role of CEO-partner at Flagship Pioneering, joining the biotech builder’s team while taking the helm at one of its startups, Kintai Therapeutics.

error: Content is protected !!